Rachna Khosla - 11 Aug 2026 Form 4 Insider Report for AMGEN INC (AMGN)

Reporting relationship: SVP, Business Development
Issuer ticker: AMGN
Reported as of: 11 Aug 2026
Net transaction value: -$1,346,499
SEC form: 4
Accepted by SEC: 13 Aug 2026, 19:05:29 UTC
Prior SEC filing: 11 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Rachna Khosla

Key filing fact

Rachna Khosla filed Form 4 for AMGEN INC (AMGN) on 13 Aug 2026.

Key facts

This page summarizes Rachna Khosla's Form 4 filing for AMGEN INC (AMGN).
4 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 13 Aug 2026, 19:05.

Change

Previous filing in this sequence was filed on 11 May 2026.
Current net transaction value: -$1,346,499.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001881332 Primary reporting owner

Khosla Rachna

Relationship: SVP, Business Development
Address: ONE AMGEN CENTER DRIVE, THOUSAND OAKS
Signature: /s/ Rachna Khosla
Signature date: 13 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AMGN transaction

Common Stock

Sale

Transaction value: $825,134
Shares: -2,000
Change %: -24%
Price: $412.57
Shares after: 6,404
Date: 11 Aug 2026
Ownership: Direct

AMGN transaction

Common Stock

Options Exercise

Transaction value
Shares: +1,252
Change %: +20%
Price: $162.60^*
Shares after: 7,656
Date: 13 Aug 2026
Ownership: Direct

AMGN transaction

Common Stock

Sale

Transaction value: $521,365
Shares: -1,252
Change %: -16%
Price: $416.43
Shares after: 6,404
Date: 13 Aug 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AMGN transaction Derivative

Nqso (Right to Buy)

Options Exercise

Transaction value
Shares: -1,252
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 13 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,252
Exercise price: $162.60

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Includes shares sold to cover the option exercise price and required withholding taxes in connection with the exercise of expiring options.

Footnote F2

These shares include 69 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited to the reporting person's unvested Restricted Stock Units and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.